Quality of care of peptic ulcer disease worldwide: A systematic analysis for the global burden of disease study 1990-2019.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
01
2022
accepted:
27
06
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
4
8
2022
Statut:
epublish
Résumé
Peptic ulcer disease (PUD) affects four million people worldwide annually and has an estimated lifetime prevalence of 5-10% in the general population. Worldwide, there are significant heterogeneities in coping approaches of healthcare systems with PUD in prevention, diagnosis, treatment, and follow-up. Quantifying and benchmarking health systems' performance is crucial yet challenging to provide a clearer picture of the potential global inequities in the quality of care. The objective of this study was to compare the health-system quality-of-care and inequities for PUD among age groups and sexes worldwide. Data were derived from the Global Burden of Disease Study 1990-2019. Principal-Component-Analysis was used to combine age-standardized mortality-to-incidence-ratio, disability-adjusted-life-years-to-prevalence-ratio, prevalence-to-incidence-ratio, and years-of-life-lost-to-years-lived-with-disability-into a single proxy named Quality-of-Care-Index (QCI). QCI was used to compare the quality of care among countries. QCI's validity was investigated via correlation with the cause-specific Healthcare-Access-and-Quality-index, which was acceptable. Inequities were presented among age groups and sexes. Gender Disparity Ratio was obtained by dividing the score of women by that of men. Global QCI was 72.6 in 1990, which increased by 14.6% to 83.2 in 2019. High-income-Asia-pacific had the highest QCI, while Central Latin America had the lowest. QCI of high-SDI countries was 82.9 in 1990, which increased to 92.9 in 2019. The QCI of low-SDI countries was 65.0 in 1990, which increased to 76.9 in 2019. There was heterogeneity among the QCI-level of countries with the same SDI level. QCI typically decreased as people aged; however, this gap was more significant among low-SDI countries. The global Gender Disparity Ratio was close to one and ranged from 0.97 to 1.03 in 100 of 204 countries. QCI of PUD improved dramatically during 1990-2019 worldwide. There are still significant heterogeneities among countries on different and similar SDI levels.
Sections du résumé
BACKGROUND
Peptic ulcer disease (PUD) affects four million people worldwide annually and has an estimated lifetime prevalence of 5-10% in the general population. Worldwide, there are significant heterogeneities in coping approaches of healthcare systems with PUD in prevention, diagnosis, treatment, and follow-up. Quantifying and benchmarking health systems' performance is crucial yet challenging to provide a clearer picture of the potential global inequities in the quality of care.
OBJECTIVE
The objective of this study was to compare the health-system quality-of-care and inequities for PUD among age groups and sexes worldwide.
METHODS
Data were derived from the Global Burden of Disease Study 1990-2019. Principal-Component-Analysis was used to combine age-standardized mortality-to-incidence-ratio, disability-adjusted-life-years-to-prevalence-ratio, prevalence-to-incidence-ratio, and years-of-life-lost-to-years-lived-with-disability-into a single proxy named Quality-of-Care-Index (QCI). QCI was used to compare the quality of care among countries. QCI's validity was investigated via correlation with the cause-specific Healthcare-Access-and-Quality-index, which was acceptable. Inequities were presented among age groups and sexes. Gender Disparity Ratio was obtained by dividing the score of women by that of men.
RESULTS
Global QCI was 72.6 in 1990, which increased by 14.6% to 83.2 in 2019. High-income-Asia-pacific had the highest QCI, while Central Latin America had the lowest. QCI of high-SDI countries was 82.9 in 1990, which increased to 92.9 in 2019. The QCI of low-SDI countries was 65.0 in 1990, which increased to 76.9 in 2019. There was heterogeneity among the QCI-level of countries with the same SDI level. QCI typically decreased as people aged; however, this gap was more significant among low-SDI countries. The global Gender Disparity Ratio was close to one and ranged from 0.97 to 1.03 in 100 of 204 countries.
CONCLUSION
QCI of PUD improved dramatically during 1990-2019 worldwide. There are still significant heterogeneities among countries on different and similar SDI levels.
Identifiants
pubmed: 35913985
doi: 10.1371/journal.pone.0271284
pii: PONE-D-22-00730
pmc: PMC9342757
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271284Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Aliment Pharmacol Ther. 2014 Mar;39(5):496-506
pubmed: 24461085
J Gastroenterol. 2014 Jan;49(1):1-8
pubmed: 24162382
Exp Hematol Oncol. 2021 Feb 8;10(1):11
pubmed: 33557940
Drugs Aging. 2007;24(10):815-28
pubmed: 17896831
Lancet. 2018 Jun 2;391(10136):2236-2271
pubmed: 29893224
Ethn Dis. 2019 Feb 21;29(Suppl 1):159-172
pubmed: 30906165
Lancet. 2012 Dec 15;380(9859):2063-6
pubmed: 23245602
Anesth Analg. 2018 May;126(5):1763-1768
pubmed: 29481436
Eur J Prev Cardiol. 2022 Mar 11;29(2):371-379
pubmed: 34041535
Jpn J Clin Oncol. 2018 Jul 01;48(7):673-683
pubmed: 29889263
Am Surg. 2011 Aug;77(8):1054-60
pubmed: 21944523
Lancet. 2017 Aug 5;390(10094):613-624
pubmed: 28242110
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54
pubmed: 31648970
Eur J Prev Cardiol. 2022 May 27;29(8):1287-1297
pubmed: 34897404
Hepatol Commun. 2022 Jul;6(7):1764-1775
pubmed: 35134275
PLoS One. 2022 Apr 21;17(4):e0263403
pubmed: 35446852
Ann Med Surg (Lond). 2018 Sep 28;35:153-157
pubmed: 30302246
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Int J Qual Health Care. 2022 Apr 22;34(2):
pubmed: 35434737
Can J Gastroenterol Hepatol. 2019 Jan 17;2019:6757524
pubmed: 30792972
Am J Med. 2019 Apr;132(4):447-456
pubmed: 30611829
PLoS One. 2022 Apr 26;17(4):e0267596
pubmed: 35472096
Helicobacter. 2017 Apr;22(2):
pubmed: 27717096
Int J Equity Health. 2021 Dec 18;20(1):259
pubmed: 34922531
J Gastroenterol Hepatol. 2018 Jul;33(7):1321-1326
pubmed: 29319200
Lancet. 2017 Jul 15;390(10091):231-266
pubmed: 28528753
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Cancer Med. 2021 Apr;10(7):2496-2508
pubmed: 33665966
Epidemiol Health. 2017 Feb 5;39:e2017006
pubmed: 28171715
Pancreatology. 2021 Dec;21(8):1443-1450
pubmed: 34561167
Best Pract Res Clin Gastroenterol. 2021 Mar-Apr;50-51:101735
pubmed: 33975689
Lancet Public Health. 2019 Mar;4(3):e159-e167
pubmed: 30851869
Lancet. 2018 Nov 17;392(10160):2203-2212
pubmed: 30195398
Lancet Public Health. 2019 Jan;4(1):e49-e73
pubmed: 30551974
Eur J Public Health. 2018 Oct 1;28(5):830-835
pubmed: 29538650
PLoS One. 2021 Feb 22;16(2):e0247120
pubmed: 33617563
J Dig Dis. 2011 Oct;12(5):319-26
pubmed: 21955424
Prz Gastroenterol. 2017;12(4):277-285
pubmed: 29358997
Sci Rep. 2021 Mar 5;11(1):5274
pubmed: 33674696
Int J Public Health. 2018 May;63(Suppl 1):187-198
pubmed: 28776255
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Aliment Pharmacol Ther. 2009 May 1;29(9):938-46
pubmed: 19220208